{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:41Z","timestamp":1791618941412,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A number of novel antidiabetic drugs have been developed. These drugs include sodium-glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is). However, the optimal medication for individuals with type 2 diabetes mellitus (T2DM) and comorbid chronic kidney disease (CKD) has not been established. To this end, this study was conducted to compare specific novel antidiabetic drugs regarding efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Cochrane Library, and Web of Science databases were searched for publications dated as of July 9, 2025. Cochrane risk of bias tool version 2.0 (RoB 2.0) was applied to measure the quality of the publications, and R 4.2.2 and Stata 15.1 were used to execute a Bayesian network meta-analysis (NMA). Primary outcomes encompassed major adverse cardiovascular events (MACEs), composite renal outcomes, and all-cause mortality (ACM). Secondary outcomes comprised adverse events (AEs), hypoglycemia, and cardiovascular death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This NMA incorporated 30 studies, involving 39,844 participants with T2DM and comorbid CKD. The interventions were ranked by performance in various outcomes using the surface under the cumulative ranking curve (SUCRA) values. Sotagliflozin ranked first in reducing MACEs (SUCRA: 90.57%). Empagliflozin ranked first in improving composite renal outcomes (SUCRA: 89.76%) and reducing ACM (SUCRA: 72.38%). Canagliflozin ranked first in reducing AEs (SUCRA: 83.37%). Dapagliflozin + exenatide ranked first in reducing hypoglycemic events (SUCRA: 77.74%). Semaglutide ranked first in reducing cardiovascular mortality (SUCRA: 89.46%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Novel antidiabetic drugs offer benefits for patients with T2DM and comorbid CKD. However, the optimal intervention varies for different outcomes. Further clinical studies are anticipated to validate these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251146144.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1750615","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:16:34Z","timestamp":1774930594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaojian","family":"Zhu","sequence":"first","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjia","family":"Wang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiru","family":"Zhang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoshi","family":"Yang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiameng","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunze","family":"Shi","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0593","article-title":"Global, regional, and national temporal trends in incidence for type 2 diabetes mellitus related chronic kidney disease from 1992 to 2021","volume":"49","author":"Cao","year":"2025","journal-title":"Diabetes Metab J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2024.06.006","article-title":"Prevalence and characteristics of chronic kidney disease in people with type 2 diabetes mellitus in the Autonomous Community of Aragon","volume":"18","author":"S\u00e1nchez-Calavera","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1186\/s40001-025-03241-8","article-title":"Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease","volume":"30","author":"Yao","year":"2025","journal-title":"Eur J Med Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: Standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0189-4","article-title":"Systematic literature review of DPP-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment","volume":"7","author":"Thomas","year":"2016","journal-title":"Diabetes Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70010","article-title":"Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-a systematic review and network meta-analysis","volume":"27","author":"Bramlage","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14702","article-title":"Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: a systematic review and network meta-analysis","volume":"24","author":"Cao","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"Bmj"},{"key":"B12","article-title":"NICE decision support unit technical support documents","volume-title":"Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment","author":"Dias","year":"2012"},{"key":"B13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/978-1-62703-059-5_25","article-title":"Bayesian inference","volume":"930","author":"Bois","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt043","article-title":"Markov chain Monte Carlo: an introduction for epidemiologists","volume":"42","author":"Hamra","year":"2013","journal-title":"Int J Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12936-017-1963-0","article-title":"Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis","volume":"16","author":"Whegang Youdom","year":"2017","journal-title":"Malar J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7326\/m15-2521","article-title":"Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials","volume":"164","author":"Trinquart","year":"2016","journal-title":"Ann Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.03.417","article-title":"Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a\/3b CKD","volume":"74","author":"Allegretti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial","volume":"61","author":"Arjona Ferreira","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12955","article-title":"A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment","volume":"71","author":"Chacra","year":"2017","journal-title":"Int J Clin Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.47583\/ijpsrr.2024.v84i03.025","article-title":"Efficacy and safety of empagliflozin versus linagliptin as add on therapy to insulin in patients of chronic kidney disease and type 2 diabetes mellitus: a randomised controlled trial","volume":"84","author":"Hameed","year":"2024","journal-title":"Int J Pharm Sci Rev Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","article-title":"Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus","volume":"38","author":"Haneda","year":"2016","journal-title":"Clin Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13126","article-title":"Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: results from a randomized, phase 3 study","volume":"11","author":"Kaku","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01467.x","article-title":"Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial","volume":"13","author":"Lukashevich","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02812.x","article-title":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study","volume":"65","author":"Nowicki","year":"2011","journal-title":"Int J Clin Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2023.13.02056202316022023","article-title":"Randomized and comparative study analyzing efficacy and safety profile of sitagliptin in early diabetic nephropathy","volume":"13","author":"Rajesh","year":"2023","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"Jama"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/dom.15287","article-title":"Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study","volume":"26","author":"Sivalingam","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15033","article-title":"Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study","volume":"25","author":"van der Aart-van der Beek","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13888","article-title":"Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type\u20092 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase\u2009III study in Japan","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2303106","article-title":"Cardiorenal impact of SGLT-2 inhibitors: A conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease","volume":"23","author":"Nevola","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: A review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-like peptide-1 receptor agonist use in people living with type 2 diabetes mellitus and chronic kidney disease: A narrative review of the key evidence with practical considerations","volume":"13","author":"G\u00f3rriz","year":"2022","journal-title":"Diabetes Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13609","article-title":"Glucagon-like peptide-1 receptor agonists and kidney outcomes","volume":"16","author":"MacIsaac","year":"2024","journal-title":"J Diabetes"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00350-4","article-title":"Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity","volume":"8","author":"Nolen-Doerr","year":"2019","journal-title":"Curr Obes Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107723","article-title":"Anti-inflammatory properties of antidiabetic drugs: A \"promised land\" in the COVID-19 era","volume":"34","author":"Katsiki","year":"2020","journal-title":"J Diabetes Complications"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000026431","article-title":"Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials","volume":"100","author":"Duan","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1750615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:16:40Z","timestamp":1774930600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1750615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":59,"alternative-id":["10.3389\/fendo.2026.1750615"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1750615","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1750615"}}